Jade Biosciences Inc Ordinary Shares JBIO 深 沪
等待开盘 07-21 09:30:00 美东时间
9.47
-0.040
-0.42%
华盛通- 最 高9.70
- 今 开9.63
- 成交量 22.26万股
- 最 低 9.355
- 昨 收 9.51
- 总市值 784.21万
- 52周最高 21.00
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 -27.65
- 委 比 -92.02%
- 总股本 82.81万
- 历史最高 1050.525
- 量 比 1.34
- 振 幅 3.63%
- 历史最低 -40.25
- 每 手 1
- 风险率 11.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in pre-market t...
07-17 18:15
Jade Biosciences to Participate in Two Upcoming Investor Conferences
Jade Biosciences announced its participation in two upcoming investor conferences. CEO Tom Frohlich and CSO Andrew King will discuss the company's pipeline, including JADE101 for immunoglobulin A nephropathy, at the H.C. Wainwright Kidney Virtual Conference on July 14 and the Stifel Biotech Summer Summit on August 13. Both events will include fireside chats and one-on-one investor meetings. Jade is focused on developing best-in-class therapies fo...
07-08 11:00
Jade Biosciences appoints Brad Dahms as CFO
Jade Biosciences (NASDAQ:JBIO) has appointed Brad Dahms as Chief Financial Officer. Mr. Dahms held management positions in various companies inlcuding most recently being Chief Financial Officer and C...
07-01 19:28
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Jade Biosciences, Inc., a biotech company focused on autoimmune diseases, has appointed Brad Dahms as its Chief Financial Officer. Dahms, with a strong track record in biotech finance and strategic leadership, joins Jade to support its growth, including advancing its lead candidate JADE101 for IgA nephropathy into clinical trials in 2025. His prior experience includes roles at IDRx, Theseus Pharmaceuticals, and Selecta Biosciences, where he led f...
07-01 11:00
美股大行评级 | 超配！Hinge Health获多家大行首予评级； Oppenheimer上调Mate目标价从665美元升至775美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1141651881139785729.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持SurgePays Inc(SURG)"买入"评级，目标价从8.75美元升至9美元</p> <p>• Ascendiant Capital：维持LiqTech Internatio
06-17 09:46
Guggenheim Upgrades Jade Biosciences to Buy, Announces $14 Price Target
Guggenheim analyst Vamil Divan upgrades Jade Biosciences (NASDAQ:JBIO) from Neutral to Buy and announces $14 price target.
06-16 21:35
Jade Biosciences Presents Detailed Preclinical Characterization Of JADE101 In Development For IgAN, Chronic Autoimmune Kidney Disease; First-In-Human Trial Expected To Begin H2 2025
Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppressionIn non-human primates, JADE101 showed a differentiated
06-09 19:03
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
Jade Biosciences, Inc. announced that new preclinical data on JADE101, its anti-APRIL monoclonal antibody for treating IgA nephropathy, will be presented at the 62nd ERA Congress in Vienna on June 6, 2025. The company will host a conference call and webcast on June 9, 2025, to discuss the data. JADE101 targets APRIL to reduce pathogenic IgA, decrease proteinuria, and preserve kidney function. A replay of the webcast will be available on the compa...
06-02 11:00
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Wedbush Reiterates Outperform on Jade Biosciences, Maintains $17 Price Target
Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maintains $17 price target.
05-15 22:57
